Neurocrine Biosciences, based in San Diego, develops pharmaceuticals for neurological disorders and employs 1,448 people. Its FDA-approved products include INGREZZA and Orilissa, with a strong clinical development pipeline.
NBIX has been in the news recently: Neurocrine Biosciences Inc. reported stronger-than-expected earnings for the first quarter of 2025, resulting in an increase in its stock price. In contrast, Palantir Technologies experienced a significant decline in its stock despite exceeding revenue expectations for the same period.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
